<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Over-the-counter cough and cold preparations: Approach to pediatric poisoning</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Over-the-counter cough and cold preparations: Approach to pediatric poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Over-the-counter cough and cold preparations: Approach to pediatric poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shan Yin, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H19880381"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Orally administered over-the-counter (OTC) cough and cold medications contain a variety of active ingredients including <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a>, antihistamines, <a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">dextromethorphan</a>, decongestants (eg, alpha adrenergic agonists such as <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> or <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">pseudoephedrine</a>), and ethanol. These medications frequently cause significant toxicity in children younger than six years of age.</p><p>Topical agents, such as imidazoline ophthalmic and nasal drops (eg, <a class="drug drug_general" data-topicid="10280" href="/d/drug information/10280.html" rel="external">tetrahydrozoline</a> or <a class="drug drug_pediatric" data-topicid="12670" href="/d/drug information/12670.html" rel="external">oxymetazoline</a>), and <a class="drug drug_pediatric" data-topicid="130062" href="/d/drug information/130062.html" rel="external">camphor</a> containing products are also frequently used to control cough and cold symptoms and can have major toxicity.</p><p>The approach to pediatric poisoning from OTC cough and cold medication in children will be reviewed here. The toxicity to children posed by individual ingredients (eg, <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a>, <a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">dextromethorphan</a>, imidazolines, or <a class="drug drug_pediatric" data-topicid="130062" href="/d/drug information/130062.html" rel="external">camphor</a>) and the use of cough and cold medications in children are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/318.html" rel="external">"Acetaminophen (paracetamol) poisoning: Management in adults and children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/305.html" rel="external">"Anticholinergic poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6488.html" rel="external">"Dextromethorphan misuse and poisoning: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6492.html" rel="external">"Dextromethorphan poisoning: Management"</a> and  <a class="medical medical_review" href="/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6486.html" rel="external">"Ethanol intoxication in children: Epidemiology, estimation of toxicity, and toxic effects"</a> and  <a class="medical medical_review" href="/d/html/6487.html" rel="external">"Ethanol intoxication in children: Clinical features, evaluation, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6509.html" rel="external">"Clonidine, xylazine, and related imidazoline poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/94636.html" rel="external">"Phenylephrine and related decongestants: Pediatric poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16629.html" rel="external">"The common cold in children: Management and prevention", section on 'Over-the-counter medications'</a>.)</p><p></p><p class="headingAnchor" id="H19880387"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>OTC cough and cold medicines are among the most commonly used medications. Several agencies, including the United States Food and Drug Administration (FDA), the Medicine and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom and Health Canada, and the American Academy of Pediatrics recommend against the use of these products in children, although age limits vary [<a href="#rid1">1-3</a>]. Prior to voluntary withdrawals of infant cold medicines, approximately 10 percent of children living in the United States had used a cough and cold medication in any given week [<a href="#rid4">4</a>]. OTC cough and cold medications are also widely used for pediatric upper respiratory infections throughout the world despite lack of proven efficacy [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/16629.html" rel="external">"The common cold in children: Management and prevention", section on 'Over-the-counter medications'</a>.)</p><p>There are approximately 30,000 pediatric (&lt;20 years) exposures to cold and cold preparations reported to United States regional poison centers annually, with about 55 percent of these occurring in children less than six years of age [<a href="#rid6">6</a>]. Approximately 25 percent of these ingestions cause moderate or major effects; fatalities in infants and children have been reported but are rare, occurring in &lt;1 percent of exploratory ingestions, and, in infants, have only been described after exposures to supratherapeutic doses [<a href="#rid1">1,7-10</a>]. Children under 2 years of age accounted for 70 to 74 percent of deaths in several studies, with child maltreatment an important concern; thus, consultation with social work is strongly advised in these cases [<a href="#rid8">8,11</a>]. In addition, cough and cold medications that contain <a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">dextromethorphan</a> are commonly used recreationally by youth and adults. (See  <a class="medical medical_review" href="/d/html/6488.html" rel="external">"Dextromethorphan misuse and poisoning: Clinical features and diagnosis", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H19880393"><span class="h1">FORMULATIONS</span><span class="headingEndMark"> — </span>OTC formulations for the treatment of cough and cold symptoms may be intended for oral or topical use. The exact constituents vary significantly between manufacturers, with hundreds of products widely available worldwide.</p><p class="headingAnchor" id="H2212176"><span class="h2">Oral agents</span><span class="headingEndMark"> — </span>OTC cough and cold preparations for oral administration include liquid and solid formulations (eg, pills, tablets, or capsules). Active ingredients, doses, and duration of action vary depending upon the manufacturer  (<a class="graphic graphic_table graphicRef94240" href="/d/graphic/94240.html" rel="external">table 1</a>) and commonly consist of one or more of the following agents [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Antihistamines (eg, <a class="drug drug_pediatric" data-topicid="13149" href="/d/drug information/13149.html" rel="external">chlorpheniramine</a>, brompheniramine, <a class="drug drug_pediatric" data-topicid="98773" href="/d/drug information/98773.html" rel="external">doxylamine</a>, or <a class="drug drug_pediatric" data-topicid="13236" href="/d/drug information/13236.html" rel="external">diphenhydramine</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Alpha<sub>1</sub> adrenergic decongestants (eg, <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a>, <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">pseudoephedrine</a>, or, outside of the United States, phenylpropanolamine) </p><p class="bulletIndent1"><span class="glyph">●</span>Antipyretic and analgesics (eg, <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> or <a class="drug drug_pediatric" data-topicid="13371" href="/d/drug information/13371.html" rel="external">ibuprofen</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Cough suppressant (typically <a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">dextromethorphan</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Expectorant (eg, <a class="drug drug_pediatric" data-topicid="13343" href="/d/drug information/13343.html" rel="external">guaifenesin</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Ethanol (adult formulations)</p><p></p><p class="headingAnchor" id="H2212183"><span class="h2">Topical agents</span><span class="headingEndMark"> — </span>OTC topical formulations typically consist of single agents that vary according to indication as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nose drops for congestion</strong> – Imidazolines (eg, <a class="drug drug_pediatric" data-topicid="12670" href="/d/drug information/12670.html" rel="external">oxymetazoline</a>, <a class="drug drug_general" data-topicid="10280" href="/d/drug information/10280.html" rel="external">tetrahydrozoline</a>, or <a class="drug drug_pediatric" data-topicid="16027" href="/d/drug information/16027.html" rel="external">naphazoline</a>) <strong>or</strong> alpha<sub>1</sub> adrenergic agents (eg, <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye drops for redness</strong> – Imidazolines (eg, <a class="drug drug_pediatric" data-topicid="12670" href="/d/drug information/12670.html" rel="external">oxymetazoline</a>, <a class="drug drug_general" data-topicid="10280" href="/d/drug information/10280.html" rel="external">tetrahydrozoline</a> or <a class="drug drug_pediatric" data-topicid="16027" href="/d/drug information/16027.html" rel="external">naphazoline</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin rubs and aerosols for cough</strong> – <a class="drug drug_pediatric" data-topicid="130062" href="/d/drug information/130062.html" rel="external">Camphor</a></p><p></p><p class="headingAnchor" id="H2212170"><span class="h2">Rationale for avoidance in children</span><span class="headingEndMark"> — </span>In randomized trials, systematic reviews, and meta-analyses, orally administered OTC medications have not been proven to work any better than placebo in children and may have serious side effects  (<a class="graphic graphic_table graphicRef67510" href="/d/graphic/67510.html" rel="external">table 2</a>). Avoidance of OTC cough and cold medications in children is based upon the following evidence:</p><p class="bulletIndent1"><span class="glyph">●</span>OTC cough and cold medications have been associated with fatal overdose in children younger than two years of age.</p><p class="bulletIndent1"><span class="glyph">●</span>OTC medications have the potential for enhanced toxicity in young children because metabolism, clearance, and drug effects may vary according to age.</p><p class="bulletIndent1"><span class="glyph">●</span>Safe dosing recommendations have not been established for children.</p><p></p><p>Thus, OTC medications are not recommended for the common cold in children younger than 6 years of age and many experts suggest not using them for children 6 to 12 years of age. (See  <a class="medical medical_review" href="/d/html/16629.html" rel="external">"The common cold in children: Management and prevention", section on 'Over-the-counter medications'</a>.) </p><p class="headingAnchor" id="H2365756"><span class="h1">APPROACH</span><span class="headingEndMark"> — </span>The approach to ingestion of over the counter cough and cold medications depends upon the presence of symptoms, the ingredients of the formulation, and the dose ingested.</p><p class="headingAnchor" id="H2365779"><span class="h2">Asymptomatic</span><span class="headingEndMark"> — </span>Many young children with exploratory ingestions of OTC cough and cold medications are asymptomatic at presentation. Proper assessment and management requires the following actions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify the exact preparation and ingredients of the ingested medication</strong> – Even though the patient is asymptomatic, serious overdose with potential toxicity may still occur, especially following ingestions of <a class="drug drug_pediatric" data-topicid="130062" href="/d/drug information/130062.html" rel="external">camphor</a>, <a class="drug drug_general" data-topicid="10280" href="/d/drug information/10280.html" rel="external">tetrahydrozoline</a> and other imidazolines, <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a>, <a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">dextromethorphan</a>, or sustained release products  (<a class="graphic graphic_table graphicRef94240" href="/d/graphic/94240.html" rel="external">table 1</a>). If possible, the clinician should obtain the container with the listed ingredients rather than relying upon the reported brand name because many different cough and cold preparations have very similar names.</p><p></p><p class="bulletIndent1">If the container cannot be obtained, consultation with a regional poison control center may be helpful to determine the range of possible toxicity based upon the brand name. (See <a class="local">'Regional poison control centers'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determine the ingested dose, need for measurement of an </strong><strong>acetaminophen</strong><strong> level, and observation</strong> – For formulations containing <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a>, referral to an emergency department and determination of serum acetaminophen concentration at least four hours after ingestion are indicated for the following patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Larger ingestions in asymptomatic children:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Acute ingestion &gt;200 mg/kg</p><p class="bulletIndent3"><span class="glyph">-</span>Chronic ingestion ≥200 mg/kg of <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> over a single 24-hour period, &gt;150 mg/kg/day over 48 hours, or &gt;100 mg/kg/day over 72 hours</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute or chronic <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> ingestions of an unknown amount </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unknown cough and cold preparation ingested</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ingestions with suicidal intent </p><p></p><p class="bulletIndent1">If obtained, the level should be plotted on the nomogram  (<a class="graphic graphic_figure graphicRef83590" href="/d/graphic/83590.html" rel="external">figure 1</a>). Depending upon other ingredients and whether they are extended release, several hours of observation with frequent assessment of vital signs after ingestion may be needed to identify delayed toxicity. (See  <a class="medical medical_review" href="/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Acute overdoses'</a> and  <a class="medical medical_review" href="/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Repeated supratherapeutic ingestion'</a>.)</p><p></p><p class="bulletIndent1">Most ingestions that are less than the total daily dose of the preparation will <strong>not</strong> result in toxicity. Frequently, regional poison control centers recommend observing children with these low dose exposures at home. Acute ingestions of <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> of &lt;200 mg/kg in children do not need serum acetaminophen levels and can be observed at home if nontoxic amounts of other ingredients in the cough and cold preparation were ingested.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Provide activated charcoal in selected patients</strong> – For asymptomatic children who have ingested a potentially toxic dose of OTC cough and cold preparations, <strong>other than</strong> products that contain <a class="drug drug_pediatric" data-topicid="130062" href="/d/drug information/130062.html" rel="external">camphor</a> or imidazolines (eg, <a class="drug drug_general" data-topicid="10280" href="/d/drug information/10280.html" rel="external">tetrahydrozoline</a>), and who present within one hour of ingestion, we recommend a single dose of activated charcoal (AC). The greatest benefit occurs if AC is given within one hour. Administration of AC more than one hour after ingestion in asymptomatic children may also be appropriate if a toxic dose of <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> has been taken. (See  <a class="medical medical_review" href="/d/html/318.html" rel="external">"Acetaminophen (paracetamol) poisoning: Management in adults and children", section on 'Gastrointestinal decontamination'</a>.)</p><p></p><p class="bulletIndent1">Because <a class="drug drug_pediatric" data-topicid="130062" href="/d/drug information/130062.html" rel="external">camphor</a> and imidazolines are rapidly absorbed and have the potential for causing sudden altered mental status (camphor and imidazolines) and seizures (camphor) soon after ingestion, AC administration after isolated camphor or imidazoline exposures is <strong>contraindicated</strong> [<a href="#rid13">13</a>]. If other agents that bind AC have been ingested, then consultation with a regional poison control center is advised to determine if the benefit of AC administration outweighs the risks. (See  <a class="medical medical_review" href="/d/html/94659.html" rel="external">"Camphor poisoning in children", section on 'Decontamination'</a> and <a class="local">'Additional resources'</a> below.)</p><p></p><p class="bulletIndent1">The recommendation of AC administration following overdose of oral OTC cough and cold medicine preparations derives from indirect evidence of benefit in volunteers, animal studies, and evidence of benefit following ingestions of other medications. Because of adverse effects, such as vomiting and dehydration, the combination of a cathartic (eg, <a class="drug drug_pediatric" data-topicid="12801" href="/d/drug information/12801.html" rel="external">sorbitol</a>) and AC should be used sparingly, if at all, and only a single dose of a cathartic should be given to any patient. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Evidence of efficacy and adverse effects'</a> and  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Cathartics'</a>.) </p><p></p><p class="headingAnchor" id="H2365814"><span class="h2">Symptomatic</span><span class="headingEndMark"> — </span>The clinician should make every effort to identify the exact formulation and the amount ingested, preferably by obtaining the container with the listed ingredients. Consultation with a regional poison control center is encouraged for all symptomatic overdoses. (See <a class="local">'Regional poison control centers'</a> below.)</p><p>Children and adolescents with symptomatic ingestions of orally administered OTC cough and cold preparations frequently have altered mental status (lethargy, coma, or agitation) and depending upon the ingredients ingested, may develop respiratory depression, severe hypertension, or seizures.</p><p>Initial management consists of timely supportive care as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Initiate continuous cardiorespiratory and pulse oximetry monitoring</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provide oxygen and support the airway and breathing as needed (see  <a class="medical medical_review" href="/d/html/6392.html" rel="external">"Pediatric advanced life support (PALS)", section on 'Respiratory distress and failure'</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measure a rapid blood glucose in patients with altered mental status or seizures and treat hypoglycemia as needed  (<a class="graphic graphic_table graphicRef83485" href="/d/graphic/83485.html" rel="external">table 3</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obtain intravenous access and blood for a serum <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> level and other studies based upon likely ingestants (see <a class="local">'Toxicity by ingredient'</a> below) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obtain a 12-lead electrocardiogram to identify arrhythmias and signs of drug effect (eg, prolonged QRS or QTc intervals after ingestion of <a class="drug drug_pediatric" data-topicid="13236" href="/d/drug information/13236.html" rel="external">diphenhydramine</a>) (see <a class="local">'Antihistamines'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treat severe agitation and elevated blood pressure with intravenous benzodiazepines (eg, <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treat elevated blood pressure  (<a class="graphic graphic_figure graphicRef62371 graphicRef75178" href="/d/graphic/62371.html" rel="external">figure 2A-B</a> and <a class="graphic graphic_table graphicRef63856" href="/d/graphic/63856.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef52646" href="/d/graphic/52646.html" rel="external">table 5</a>) complicated by seizures, pulmonary edema, myocardial ischemia, or vision changes with <a class="drug drug_pediatric" data-topicid="12700" href="/d/drug information/12700.html" rel="external">phentolamine</a> (0.1 mg/kg, maximum dose 5 mg) or a direct-acting antihypertensive agent (eg, sodium <a class="drug drug_pediatric" data-topicid="12648" href="/d/drug information/12648.html" rel="external">nitroprusside</a>) (see  <a class="medical medical_review" href="/d/html/94636.html" rel="external">"Phenylephrine and related decongestants: Pediatric poisoning", section on 'Hypertensive emergency'</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Manage toxin-induced seizures as shown in the table  (<a class="graphic graphic_table graphicRef55368" href="/d/graphic/55368.html" rel="external">table 6</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with respiratory depression and coma, provide a trial of <a class="drug drug_pediatric" data-topicid="12628" href="/d/drug information/12628.html" rel="external">naloxone</a> in patients, especially in young children who have ingested <a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">dextromethorphan</a> or imidazolines (eg, <a class="drug drug_general" data-topicid="10280" href="/d/drug information/10280.html" rel="external">tetrahydrozoline</a>) (see  <a class="medical medical_review" href="/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents", section on 'Naloxone'</a> and  <a class="medical medical_review" href="/d/html/6509.html" rel="external">"Clonidine, xylazine, and related imidazoline poisoning", section on 'Coma with respiratory depression'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional management, including gastrointestinal decontamination, is determined by the specific agents ingested (see <a class="local">'Toxicity by ingredient'</a> below) </p><p></p><p>In some patients, poisoning from OTC cough and cold preparations can have a mixed presentation. As an example, toxicity from a formulation that contains antihistamines and decongestants may present with lethargy, bradycardia, and hypertension [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H2365820"><span class="h2">Disposition</span><span class="headingEndMark"> — </span>The clinician can discharge asymptomatic patients who ingested an OTC cough and cold preparation if the following conditions are met:</p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic at four to six hours after exposure and a sustained release product has <strong>not</strong> been ingested</p><p class="bulletIndent1"><span class="glyph">●</span>No evidence of suicidal intent</p><p class="bulletIndent1"><span class="glyph">●</span>A nontoxic <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> level obtained at least four hours after acute ingestion in the following circumstances:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ingested dose &gt;200 mg/kg</p><p class="bulletIndent2"><span class="glyph">•</span>Unknown amount of <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> consumed</p><p class="bulletIndent2"><span class="glyph">•</span>Unknown cough and cold preparation ingested</p><p></p><p class="bulletIndent1">Patients with chronic supratherapeutic dosing of <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> over more than 24 hours warrant additional evaluation as discussed separately. (See  <a class="medical medical_review" href="/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Repeated supratherapeutic ingestion'</a>.) </p><p></p><p>Asymptomatic patients who are suicidal require psychiatric evaluation prior to discharge and should also be carefully evaluated for co-ingestions, including the measurement of an <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> level.</p><p>Asymptomatic patients who ingested sustained release alpha<sub>1</sub> adrenergic decongestants (<a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a>, <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">pseudoephedrine</a>, or phenylpropanolamine [not available in the United States]) warrant observation and frequent measurement of blood pressure for six hours to monitor for delayed hypertension. (See  <a class="medical medical_review" href="/d/html/94636.html" rel="external">"Phenylephrine and related decongestants: Pediatric poisoning", section on 'Asymptomatic'</a>.)</p><p>Persistently symptomatic patients warrant hospital admission.</p><p>Intensive care admission is appropriate for patients with the following toxicity:</p><p class="bulletIndent1"><span class="glyph">●</span>Complicated courses marked by severe hypertension, seizures, apnea, or coma</p><p class="bulletIndent1"><span class="glyph">●</span>Central anticholinergic syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Serotonin syndrome</p><p></p><p class="headingAnchor" id="H26320082"><span class="h1">TOXICITY BY INGREDIENT</span></p><p class="headingAnchor" id="H24422857"><span class="h2">Acetaminophen</span><span class="headingEndMark"> — </span>Many combination OTC cough and cold medications contain <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> and the possibility of significant acetaminophen poisoning caused by acute or repeated supratherapeutic ingestions of these formulations should <strong>not</strong> be overlooked. Rapid identification of acute acetaminophen overdose is essential because the antidote, <a class="drug drug_pediatric" data-topicid="13239" href="/d/drug information/13239.html" rel="external">acetylcysteine</a>, is most effective when given within eight to 10 hours of an acute acetaminophen ingestion. (See  <a class="medical medical_review" href="/d/html/318.html" rel="external">"Acetaminophen (paracetamol) poisoning: Management in adults and children", section on 'Acetylcysteine administration and monitoring'</a>.) </p><p>The diagnostic approach to <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> poisoning varies by the type of exposure:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute</strong> – Most patients with serious <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> exposure from an acute OTC cough and cold preparation overdose will be symptomatic from other ingredients (eg, antihistamines, decongestants, or <a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">dextromethorphan</a>)  (<a class="graphic graphic_table graphicRef94240" href="/d/graphic/94240.html" rel="external">table 1</a>). In these patients, a serum acetaminophen concentration should be measured between 4 and 24 hours after an acute overdose and plotted on the acetaminophen nomogram to determine the need for antidotal therapy with <a class="drug drug_pediatric" data-topicid="13239" href="/d/drug information/13239.html" rel="external">acetylcysteine</a>  (<a class="graphic graphic_figure graphicRef83590" href="/d/graphic/83590.html" rel="external">figure 1</a>). Gastrointestinal decontamination with activated charcoal may be beneficial for several hours after acetaminophen ingestion in selected patients. The diagnosis and treatment of acute acetaminophen poisoning in children is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Acetaminophen concentration'</a> and  <a class="medical medical_review" href="/d/html/318.html" rel="external">"Acetaminophen (paracetamol) poisoning: Management in adults and children", section on 'Patient with reliable history and acute ingestion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic</strong> – Diagnosis of chronic <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> intoxication (repeated excessive dosing) from multiple supratherapeutic doses of an OTC cough and cold medication is often difficult and requires the combination of astute history-taking and recognition of typical clinical and laboratory abnormalities. Clinicians must specifically ask about the dose and frequency of administration since patients and caregivers may not include OTC cough and cold medications when asked about potentially toxic drugs. Signs and symptoms are insidious in onset, often nonspecific, and easily confused with alternative diagnoses (eg, viral syndrome for which the preparation is being given). Serum concentrations of acetaminophen in this setting do not correlate with toxicity but help to identify exposure. Supportive laboratory findings include elevation of serum liver enzymes (eg, alanine and aspartate aminotransferase) and total serum bilirubin and a prolonged prothrombin time. Recognition and treatment of chronic acetaminophen overdose in children is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/17161.html" rel="external">"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Acetaminophen concentration'</a> and  <a class="medical medical_review" href="/d/html/318.html" rel="external">"Acetaminophen (paracetamol) poisoning: Management in adults and children", section on 'Inappropriate therapeutic dosing'</a>.) </p><p></p><p class="headingAnchor" id="H19880406"><span class="h2">Antihistamines</span><span class="headingEndMark"> — </span>The common antihistamines found in OTC cough and cold formulations have traditionally included first-generation antihistamines such as <a class="drug drug_pediatric" data-topicid="13149" href="/d/drug information/13149.html" rel="external">chlorpheniramine</a>, brompheniramine, <a class="drug drug_pediatric" data-topicid="98773" href="/d/drug information/98773.html" rel="external">doxylamine</a>, and <a class="drug drug_pediatric" data-topicid="13236" href="/d/drug information/13236.html" rel="external">diphenhydramine</a> [<a href="#rid14">14,15</a>]. At lower doses, these agents can cause sedation and mild lethargy through effects on the H<sub>1</sub> histamine receptors.</p><p>More recently, second-generation antihistamines such as <a class="drug drug_pediatric" data-topicid="12563" href="/d/drug information/12563.html" rel="external">loratadine</a>, <a class="drug drug_pediatric" data-topicid="13141" href="/d/drug information/13141.html" rel="external">cetirizine</a>, and <a class="drug drug_pediatric" data-topicid="13300" href="/d/drug information/13300.html" rel="external">fexofenadine</a> have become common ingredients in cough syrups. Most children remain asymptomatic, even after large overdoses (over 60 times the maximum recommended therapeutic dose) [<a href="#rid16">16</a>]. Among symptomatic patients, minor drowsiness or restlessness without major toxicity is typical.</p><p>With higher doses of first-generation antihistamines, anticholinergic poisoning may occur with typical findings associated with the anticholinergic toxidrome as follows (see  <a class="medical medical_review" href="/d/html/305.html" rel="external">"Anticholinergic poisoning", section on 'Clinical features of overdose'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Flushed and dry skin</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthermia</p><p class="bulletIndent1"><span class="glyph">●</span>Dilated pupils and blurry vision</p><p class="bulletIndent1"><span class="glyph">●</span>Agitation, tremor, picking movements, delirium, hallucinations, coma, and, especially in children, seizures</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary retention and absent bowel sounds</p><p></p><p>A rapid overview of clinical assessment and management of central anticholinergic syndrome is provided in the table  (<a class="graphic graphic_table graphicRef74091" href="/d/graphic/74091.html" rel="external">table 7</a>) and discussed separately. (See  <a class="medical medical_review" href="/d/html/305.html" rel="external">"Anticholinergic poisoning", section on 'Management'</a>.)</p><p>While both peripheral and central symptoms are usually present, anticholinergic toxicity can also present with isolated CNS symptoms of delirium, hallucinations, and agitation. A commonly used mnemonic for anticholinergic toxicity is "hot as a hare, blind as a bat, dry as a bone, red as a beet, and mad as a hatter."</p><p>Agitation and delirium caused by anticholinergic poisoning is initially treated with benzodiazepines (<a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> 0.1 mg/kg; maximum dose: 2 mg). Some experts recommend that patients with anticholinergic poisoning manifesting both peripheral signs (eg, flushing, dry skin, and hyperthermia) and central effects (agitated delirium, seizures) receive <a class="drug drug_pediatric" data-topicid="12703" href="/d/drug information/12703.html" rel="external">physostigmine</a>. However, this recommendation is controversial and consultation with a medical toxicologist or regional poison center is encouraged before physostigmine is given. (See  <a class="medical medical_review" href="/d/html/305.html" rel="external">"Anticholinergic poisoning"</a> and <a class="local">'Additional resources'</a> below.)</p><p>In addition to anticholinergic effects, <a class="drug drug_pediatric" data-topicid="13236" href="/d/drug information/13236.html" rel="external">diphenhydramine</a> overdose has rarely been associated with prolongation of the QRS and corrected QT intervals and tachyarrhythmias (eg, supraventricular and ventricular tachycardia) [<a href="#rid17">17,18</a>]. Thus, a 12 lead EKG is warranted to identify such changes when diphenhydramine is ingested. Management of toxin-induced QRS and QTc prolongation are discussed separately. (See  <a class="medical medical_review" href="/d/html/295.html" rel="external">"Tricyclic antidepressant poisoning", section on 'Sodium bicarbonate for cardiac toxicity'</a> and  <a class="medical medical_review" href="/d/html/315.html" rel="external">"First-generation (typical) antipsychotic medication poisoning", section on 'QT interval prolongation'</a>.) </p><p class="headingAnchor" id="H14696055"><span class="h2">Dextromethorphan</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">Dextromethorphan</a> (d-3-methoxy-N-methylmorphinan, DXM) is an OTC cough suppressant that is commonly diverted for illicit recreational use. It shares pharmacological similarities with <a class="drug drug_pediatric" data-topicid="13398" href="/d/drug information/13398.html" rel="external">ketamine</a> and phencyclidine (PCP). Rarely, DXM poisoning is associated with profound coma and, in young children, respiratory depression that is responsive to <a class="drug drug_pediatric" data-topicid="12628" href="/d/drug information/12628.html" rel="external">naloxone</a>.</p><p>Following acute overdose <a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">dextromethorphan</a> produces several characteristic physical findings that may be variably present depending upon the dose ingested as follows (see  <a class="medical medical_review" href="/d/html/6488.html" rel="external">"Dextromethorphan misuse and poisoning: Clinical features and diagnosis", section on 'Toxic dose'</a> and  <a class="medical medical_review" href="/d/html/6488.html" rel="external">"Dextromethorphan misuse and poisoning: Clinical features and diagnosis", section on 'Clinical features'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Neurobehavioral changes that include euphoria, hallucinations, inappropriate laughing, psychosis with dissociative features, agitation, and coma</p><p class="bulletIndent1"><span class="glyph">●</span>Tachycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Dilated pupils</p><p class="bulletIndent1"><span class="glyph">●</span>Nystagmus</p><p class="bulletIndent1"><span class="glyph">●</span>Diaphoresis (in the absence of anticholinergic co-ingestion)</p><p class="bulletIndent1"><span class="glyph">●</span>"Zombie-like" ataxic gait</p><p></p><p>Agitation in association with severe <a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">dextromethorphan</a> intoxication may also result in hyperthermia and metabolic acidosis with potential for rhabdomyolysis.</p><p>In addition, <a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">dextromethorphan</a> may precipitate the serotonin syndrome (altered mental status, seizures, autonomic instability, and/or muscular hypertonicity) in overdose and when combined with monoamine oxidase inhibitors, serotonin specific reuptake inhibitors, <a class="drug drug_pediatric" data-topicid="12555" href="/d/drug information/12555.html" rel="external">linezolid</a>, <a class="drug drug_pediatric" data-topicid="12580" href="/d/drug information/12580.html" rel="external">meperidine</a>, <a class="drug drug_pediatric" data-topicid="12892" href="/d/drug information/12892.html" rel="external">tramadol</a>, and other serotonergic agents. Serotonin syndrome is a life-threatening condition. Recognition, differential diagnosis, and treatment are provided in the rapid overview  (<a class="graphic graphic_table graphicRef73400" href="/d/graphic/73400.html" rel="external">table 8</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)", section on 'Management'</a>.)</p><p>The management of <a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">dextromethorphan</a> poisoning is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6492.html" rel="external">"Dextromethorphan poisoning: Management"</a>.)</p><p class="headingAnchor" id="H14696078"><span class="h2">Ethanol</span><span class="headingEndMark"> — </span>Although most pediatric cough and cold formulations do not contain ethanol, it is a frequent additive to adult OTC cough and cold preparations. Given the concentration of ethanol in most preparations, significant inebriation is unlikely in older patients, but infants and younger children are at risk for hypoglycemia. (See  <a class="medical medical_review" href="/d/html/6486.html" rel="external">"Ethanol intoxication in children: Epidemiology, estimation of toxicity, and toxic effects", section on 'Toxic dose'</a> and  <a class="medical medical_review" href="/d/html/6486.html" rel="external">"Ethanol intoxication in children: Epidemiology, estimation of toxicity, and toxic effects", section on 'Ethanol-induced hypoglycemia'</a>.)</p><p>A rapid overview of clinical assessment and emergent management of ethanol overdose is provided in the table  (<a class="graphic graphic_table graphicRef76987" href="/d/graphic/76987.html" rel="external">table 9</a>) and discussed separately. (See  <a class="medical medical_review" href="/d/html/6487.html" rel="external">"Ethanol intoxication in children: Clinical features, evaluation, and management", section on 'Management'</a>.)</p><p class="headingAnchor" id="H19880424"><span class="h2">Phenylephrine and similar decongestants</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">Phenylephrine</a>, <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">pseudoephedrine</a>, and phenylpropanolamine (not available in the United States) are substituted phenethylamines and structurally similar to amphetamine and methamphetamine.</p><p>Overdose of decongestants typically produces sympathomimetic findings as follows (see  <a class="medical medical_review" href="/d/html/94636.html" rel="external">"Phenylephrine and related decongestants: Pediatric poisoning", section on 'Clinical features and diagnosis'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension, which may be severe and associated with seizures, altered mental status, heart failure, or kidney damage</p><p class="bulletIndent1"><span class="glyph">●</span>Tachycardia or reflex bradycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Mydriasis</p><p class="bulletIndent1"><span class="glyph">●</span>Diaphoresis</p><p class="bulletIndent1"><span class="glyph">●</span>Agitation</p><p></p><p>Reflex bradycardia is more likely to occur following exposure to selective alpha<sub>1</sub> adrenergic agonists (eg, <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> or phenylpropanolamine).</p><p>Serious complications can occur after decongestant overdose including seizures, rhabdomyolysis, cardiac dysrhythmias, myocardial infarction, cerebral vascular accident, bowel infarction, and death. The risk of complications is largely determined by the severity of hypertension.</p><p>The management of <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a> overdose is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/94636.html" rel="external">"Phenylephrine and related decongestants: Pediatric poisoning", section on 'Management'</a>.)</p><p class="headingAnchor" id="H26319727"><span class="h2">Tetrahydrozoline and similar imidazolines</span><span class="headingEndMark"> — </span>A rapid overview provides the approach to recognition and treatment of imidazoline poisoning  (<a class="graphic graphic_table graphicRef63110" href="/d/graphic/63110.html" rel="external">table 10</a>). <a class="drug drug_pediatric" data-topicid="12628" href="/d/drug information/12628.html" rel="external">Naloxone</a> has successfully reversed toxicity in case reports of <a class="drug drug_general" data-topicid="10280" href="/d/drug information/10280.html" rel="external">tetrahydrozoline</a> overdose. (See  <a class="medical medical_review" href="/d/html/6509.html" rel="external">"Clonidine, xylazine, and related imidazoline poisoning", section on 'Coma with respiratory depression'</a>.)</p><p>Imidazolines (eg, <a class="drug drug_pediatric" data-topicid="12670" href="/d/drug information/12670.html" rel="external">oxymetazoline</a>, <a class="drug drug_general" data-topicid="10280" href="/d/drug information/10280.html" rel="external">tetrahydrozoline</a>, and <a class="drug drug_pediatric" data-topicid="16027" href="/d/drug information/16027.html" rel="external">naphazoline</a>) are alpha<sub>2</sub> adrenergic agonists that are structurally similar to <a class="drug drug_pediatric" data-topicid="13171" href="/d/drug information/13171.html" rel="external">clonidine</a> and are available in topical nasal decongestants and eye drops. Their therapeutic action is through local vasoconstriction in the nasal passages or the eyes via alpha<sub>2</sub> adrenergic activation.</p><p>While systemic toxicity is uncommon after topical application, these agents can produce significant toxicity if taken orally. Clinical findings include lethargy, coma, apnea, bradycardia, hypotension, and hypothermia similar to <a class="drug drug_pediatric" data-topicid="13171" href="/d/drug information/13171.html" rel="external">clonidine</a> ingestion. (See  <a class="medical medical_review" href="/d/html/6509.html" rel="external">"Clonidine, xylazine, and related imidazoline poisoning"</a>.)</p><p class="headingAnchor" id="H19880503"><span class="h2">Camphor</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="130062" href="/d/drug information/130062.html" rel="external">Camphor</a>, a terpenoid hydrocarbon, is marketed for topical use for cough and nasal decongestion and formulations may combine it with menthol (eg, Vick's vaporub).</p><p>Key findings of <a class="drug drug_pediatric" data-topicid="130062" href="/d/drug information/130062.html" rel="external">camphor</a> poisoning include:</p><p class="bulletIndent1"><span class="glyph">●</span>History of oral ingestion or topical exposure to a camphor-containing product</p><p class="bulletIndent1"><span class="glyph">●</span>Seizures which may be the first sign of exposure</p><p class="bulletIndent1"><span class="glyph">●</span>Strong medicinal smell on the breath or if a topical exposure, on the skin</p><p class="bulletIndent1"><span class="glyph">●</span>Oropharyngeal irritation such as burning or stinging</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea, vomiting, and abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Other central nervous system effects, including agitation, confusion, myoclonus, hyperreflexia, lethargy, and/or coma</p><p></p><p>History of <a class="drug drug_pediatric" data-topicid="130062" href="/d/drug information/130062.html" rel="external">camphor</a> exposure is particularly important because many caregivers may be unaware of the dangers of camphor and not mention its use when seeking medical care.</p><p>The management of <a class="drug drug_pediatric" data-topicid="130062" href="/d/drug information/130062.html" rel="external">camphor</a> poisoning in children is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/94659.html" rel="external">"Camphor poisoning in children", section on 'Management'</a>.) </p><p class="headingAnchor" id="H19880569"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The general prevention of pediatric poisoning is discussed separately. (See  <a class="medical medical_review" href="/d/html/2873.html" rel="external">"Prevention of poisoning in children"</a>.)</p><p>Based upon poison control center reports, voluntary withdrawal of cough and cold formulations for children in the United States in 2007 was initially associated with a 33 percent decrease in unintentional exposures to these medications in children younger than 12 years of age and more than a 50 percent decline in ingestions among infants younger than two years of age [<a href="#rid19">19</a>]. However, poisoning from OTC cough and cold medicine remains a persistent problem. Proposed contributing factors include parental misunderstanding of labeling as well as caregivers who are unaware of or are disregarding US Food and Drug Administration (FDA) recommendations [<a href="#rid20">20-22</a>].</p><p>Thus, education of caregivers regarding the proper treatment of the common cold in children and reinforcing the avoidance of OTC cough and cold medications in children are additional primary prevention strategies that clinicians may incorporate into their practice. (See  <a class="medical medical_review" href="/d/html/16629.html" rel="external">"The common cold in children: Management and prevention", section on 'Caregiver education'</a>.)</p><p class="headingAnchor" id="H6011305"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H685337091"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H641165982"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112688.html" rel="external">"Society guideline links: Poisoning prevention"</a>.)</p><p class="headingAnchor" id="H73241441"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulations </strong>– Over-the-counter (OTC) cough and cold preparations for oral administration include liquid and solid formulations (eg, pills, tablets, or capsules). Active ingredients, doses, and duration of action vary depending upon the manufacturer  (<a class="graphic graphic_table graphicRef94240" href="/d/graphic/94240.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef67510" href="/d/graphic/67510.html" rel="external">table 2</a>) and frequently include (see <a class="local">'Formulations'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">Acetaminophen</a></p><p class="bulletIndent2"><span class="glyph">•</span>Antihistamines</p><p class="bulletIndent2"><span class="glyph">•</span>Alpha<sub>1</sub> adrenergic decongestants</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13220" href="/d/drug information/13220.html" rel="external">Dextromethorphan</a></p><p class="bulletIndent2"><span class="glyph">•</span>Ethanol (adult formulations)</p><p></p><p class="bulletIndent1">OTC topical formulations include (see <a class="local">'Formulations'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Imidazolines (<a class="drug drug_general" data-topicid="10280" href="/d/drug information/10280.html" rel="external">tetrahydrozoline</a>)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">Phenylephrine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="130062" href="/d/drug information/130062.html" rel="external">Camphor</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach </strong>– The clinician should make every effort to identify the exact formulation and the amount ingested, preferably by obtaining the container with the listed ingredients. Consultation with a regional poison control center is encouraged for all symptomatic overdoses. (See <a class="local">'Approach'</a> above and <a class="local">'Additional resources'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determine need to measure an </strong><strong>acetaminophen</strong><strong> concentration</strong> –<strong> </strong>Children who have acutely ingested an OTC cough and cold preparation that contains <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> should have a serum level obtained at least four hours after ingestion and plotted on the nomogram  (<a class="graphic graphic_figure graphicRef83590" href="/d/graphic/83590.html" rel="external">figure 1</a>) in the following circumstances (see <a class="local">'Asymptomatic'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unknown cough and cold preparation ingested</p><p class="bulletIndent2"><span class="glyph">•</span>Patients with suicidal intent</p><p class="bulletIndent2"><span class="glyph">•</span>Acute <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> ingestion &gt;200 mg/kg</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> ingestion ≥200 mg/kg over a single 24-hour period, &gt;150 mg/kg/day over 48 hours, or &gt;100 mg/kg/day over 72 hours</p><p class="bulletIndent2"><span class="glyph">•</span>Acute or chronic <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> ingestion of an unknown amount</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal decontamination</strong> – In an asymptomatic child who has ingested a potentially toxic dose of OTC cough and cold preparations, <strong>other than</strong> products that contain <a class="drug drug_pediatric" data-topicid="130062" href="/d/drug information/130062.html" rel="external">camphor</a> or imidazolines (eg, <a class="drug drug_general" data-topicid="10280" href="/d/drug information/10280.html" rel="external">tetrahydrozoline</a>), and who presents within one hour of ingestion, we recommend a single dose of activated charcoal (AC) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). The greatest benefit occurs if AC is given within one hour. Administration of AC more than one hour after ingestion in an asymptomatic child may also be appropriate if a toxic dose of <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> has been taken. (See <a class="local">'Asymptomatic'</a> above.)</p><p></p><p class="bulletIndent1">Because <a class="drug drug_pediatric" data-topicid="130062" href="/d/drug information/130062.html" rel="external">camphor</a> and imidazolines are rapidly absorbed and have the potential for causing sudden altered mental status (camphor and imidazolines) and seizures (camphor) soon after ingestion, AC administration after isolated camphor or imidazoline exposures is <strong>contraindicated</strong>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic patient after ingestion</strong> – Children and adolescents with symptomatic ingestions of orally administered OTC cough and cold preparations frequently have altered mental status (lethargy, coma, or agitation) and, depending upon the ingredients ingested, may develop respiratory depression, severe hypertension, or seizures. (See <a class="local">'Symptomatic'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Initial management consists of timely supportive care. Additional management, including gastrointestinal decontamination, is determined by the specific agents ingested (see <a class="local">'Symptomatic'</a> above and <a class="local">'Toxicity by ingredient'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High doses of antihistamines with anticholinergic syndrome  (<a class="graphic graphic_table graphicRef74091" href="/d/graphic/74091.html" rel="external">table 7</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Dextromethorphan-precipitated serotonin syndrome  (<a class="graphic graphic_table graphicRef73400" href="/d/graphic/73400.html" rel="external">table 8</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Ethanol  (<a class="graphic graphic_table graphicRef76987" href="/d/graphic/76987.html" rel="external">table 9</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Imidazolines  (<a class="graphic graphic_table graphicRef63110" href="/d/graphic/63110.html" rel="external">table 10</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disposition</strong> – The clinician can discharge asymptomatic patients who acutely ingested an OTC cough and cold preparation if the following conditions are met (see <a class="local">'Disposition'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Asymptomatic at four to six hours after exposure and a sustained release product has <strong>not</strong> been ingested</p><p class="bulletIndent2"><span class="glyph">•</span>No evidence of suicidal intent</p><p class="bulletIndent2"><span class="glyph">•</span>When indicated, a nontoxic <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> level obtained at least four hours after acute ingestion for preparations containing acetaminophen and when ingredients are unknown</p><p></p><p class="bulletIndent1">Asymptomatic patients who are suicidal require psychiatric evaluation prior to discharge and should also be carefully evaluated for co-ingestions, including the measurement of an <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> level.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">US Food and Drug Administration. Public Health Advisory: FDA recommends that over-the-counter (OTC) cough and cold products not be used for infants and children under 2 years of age. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/drugsafetyinformationforheathcareprofessionals/publichealthadvisories/ucm051137.htm (Accessed 12/31/13).</li><li><a class="nounderline abstract_t">Kuehn BM. Debate continues over the safety of cold and cough medicines for children. JAMA 2008; 300:2354.</a></li><li><a class="nounderline abstract_t">Budnitz DS, Lovegrove MC, Rose KO. Adherence to label and device recommendations for over-the-counter pediatric liquid medications. Pediatrics 2014; 133:e283.</a></li><li><a class="nounderline abstract_t">Vernacchio L, Kelly JP, Kaufman DW, Mitchell AA. Cough and cold medication use by US children, 1999-2006: results from the slone survey. Pediatrics 2008; 122:e323.</a></li><li class="breakAll">Cough and cold remedies for the treatment of acute respiratory infections in young children. Department of Child and Adolescent Health and Development. World Health Organization. 2001. Available at http://www.who.int/maternal_child_adolescent/documents/fch_cah_01_02/en/ (Accessed March 5, 2014).</li><li><a class="nounderline abstract_t">Mowry JB, Spyker DA, Brooks DE, et al. 2014 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 32nd Annual Report. Clin Toxicol (Phila) 2015; 53:962.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. MMWR Morb Mortal Wkly Rep 2007; 56:1.</a></li><li><a class="nounderline abstract_t">Dart RC, Paul IM, Bond GR, et al. Pediatric fatalities associated with over the counter (nonprescription) cough and cold medications. Ann Emerg Med 2009; 53:411.</a></li><li><a class="nounderline abstract_t">Green JL, Wang GS, Reynolds KM, et al. Safety Profile of Cough and Cold Medication Use in Pediatrics. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Halmo LS, Wang GS, Reynolds KM, et al. Pediatric Fatalities Associated With Over-the-Counter Cough and Cold Medications. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Gaw CE, Curry AE, Osterhoudt KC, et al. Characteristics of Fatal Poisonings Among Infants and Young Children in the United States. Pediatrics 2023; 151.</a></li><li><a class="nounderline abstract_t">Kelly LF. Pediatric cough and cold preparations. Pediatr Rev 2004; 25:115.</a></li><li><a class="nounderline abstract_t">Manoguerra AS, Erdman AR, Wax PM, et al. Camphor Poisoning: an evidence-based practice guideline for out-of-hospital management. Clin Toxicol (Phila) 2006; 44:357.</a></li><li><a class="nounderline abstract_t">Gunn VL, Taha SH, Liebelt EL, Serwint JR. Toxicity of over-the-counter cough and cold medications. Pediatrics 2001; 108:E52.</a></li><li class="breakAll">Tomassoni AJ, Weisman RS. Antihistamines and decongestants. In: Goldfrank's Toxicologic Emergencies, 9th ed, Nelson LS, Lewin NA, Howland MA, et al (Eds), McGraw Hill Medical, New York 2011. p.748.</li><li><a class="nounderline abstract_t">Verdu E, Blanc-Brisset I, Meyer G, et al. Second-generation antihistamines: a study of poisoning in children. Clin Toxicol (Phila) 2020; 58:275.</a></li><li><a class="nounderline abstract_t">Cole JB, Stellpflug SJ, Gross EA, Smith SW. Wide complex tachycardia in a pediatric diphenhydramine overdose treated with sodium bicarbonate. Pediatr Emerg Care 2011; 27:1175.</a></li><li><a class="nounderline abstract_t">Al-Abri SA, Woodburn C, Olson KR, Kearney TE. Ventricular dysrhythmias associated with poisoning and drug overdose: a 10-year review of statewide poison control center data from California. Am J Cardiovasc Drugs 2015; 15:43.</a></li><li><a class="nounderline abstract_t">Mazer-Amirshahi M, Reid N, van den Anker J, Litovitz T. Effect of cough and cold medication restriction and label changes on pediatric ingestions reported to United States poison centers. J Pediatr 2013; 163:1372.</a></li><li><a class="nounderline abstract_t">Lokker N, Sanders L, Perrin EM, et al. Parental misinterpretations of over-the-counter pediatric cough and cold medication labels. Pediatrics 2009; 123:1464.</a></li><li><a class="nounderline abstract_t">Hanoch Y, Gummerum M, Miron-Shatz T, Himmelstein M. Parents' decision following the Food and Drug Administration recommendation: the case of over-the-counter cough and cold medication. Child Care Health Dev 2010; 36:795.</a></li><li><a class="nounderline abstract_t">Lazarus SG, Lanski SL, Smith AS, Simon HK. Cold preparation use in young children after FDA warnings: do concerns still exist? Clin Pediatr (Phila) 2013; 52:534.</a></li></ol></div><div id="topicVersionRevision">Topic 16258 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/drugsafetyinformationforheathcareprofessionals/publichealthadvisories/ucm051137.htm" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : US Food and Drug Administration. Public Health Advisory: FDA recommends that over-the-counter (OTC) cough and cold products not be used for infants and children under 2 years of age. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/drugsafetyinformationforheathcareprofessionals/publichealthadvisories/ucm051137.htm (Accessed 12/31/13).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19033577" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Debate continues over the safety of cold and cough medicines for children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24394683" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Adherence to label and device recommendations for over-the-counter pediatric liquid medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676518" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cough and cold medication use by US children, 1999-2006: results from the slone survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676518" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cough and cold medication use by US children, 1999-2006: results from the slone survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26624241" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2014 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 32nd Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218934" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Infant deaths associated with cough and cold medications--two states, 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19101060" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pediatric fatalities associated with over the counter (nonprescription) cough and cold medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28562262" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Safety Profile of Cough and Cold Medication Use in Pediatrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34607934" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pediatric Fatalities Associated With Over-the-Counter Cough and Cold Medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36897244" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Characteristics of Fatal Poisonings Among Infants and Young Children in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15060179" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pediatric cough and cold preparations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16809137" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Camphor Poisoning: an evidence-based practice guideline for out-of-hospital management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533370" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Toxicity of over-the-counter cough and cold medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533370" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Toxicity of over-the-counter cough and cold medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31271318" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Second-generation antihistamines: a study of poisoning in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22158278" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Wide complex tachycardia in a pediatric diphenhydramine overdose treated with sodium bicarbonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25567789" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ventricular dysrhythmias associated with poisoning and drug overdose: a 10-year review of statewide poison control center data from California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23769500" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of cough and cold medication restriction and label changes on pediatric ingestions reported to United States poison centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19482755" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Parental misinterpretations of over-the-counter pediatric cough and cold medication labels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456376" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Parents' decision following the Food and Drug Administration recommendation: the case of over-the-counter cough and cold medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23539689" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cold preparation use in young children after FDA warnings: do concerns still exist?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
